Practice Point®: Pulmonology

How can emerging evidence and expert recommendations be translated into practical decisions for patients with IPF and other fibrotic ILDs? In this interactive Q&A, leading ILD specialists address real-world challenges, including managing antifibrotic adverse effects, addressing cough associated with inhaled treprostinil, assessing prognostic risk, and managing incidental interstitial lung abno...

The treatment landscape for IPF and PPF is evolving rapidly, creating new opportunities for more personalized care. Explore the latest clinical evidence from the FIBRONEER program evaluating nerandomilast and the TETON trials evaluating inhaled treprostinil, alongside emerging therapies such as admilparant and deupirfenidone. Expert faculty examine novel mechanisms of action, treatment tolerabilit...

Antifibrotic therapies can slow disease progression in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), but adverse effects and treatment discontinuation remain important challenges. Through a patient case and interactive clinical decision-making, explore practical approaches to managing gastrointestinal intolerance, adjusting doses, implementing temporary treatment in...

When should persistent cough and dyspnea raise suspicion for interstitial lung disease (ILD) rather than more common respiratory conditions? Follow a 68-year-old patient whose nine-month diagnostic journey highlights missed clinical clues, delayed imaging, and opportunities for earlier intervention. Through interactive case-based questions, explore how clinical findings, pulmonary function testing...

Interstitial lung disease (ILD) encompasses a diverse group of disorders, making early recognition, accurate diagnosis, and timely referral challenging. In this expert-led module, explore the clinical, genetic, and environmental factors contributing to ILD heterogeneity, along with racial, ethnic, and socioeconomic disparities that influence patient outcomes. Through interactive audience polling a...

This module focuses on sustaining effective PAH management over time by integrating ongoing risk assessment with treatment persistence, tolerability, and evolving patient needs. It examines when continued therapy, escalation, transition, or carefully selected de-escalation may be appropriate, while emphasizing that failure to achieve or maintain low-risk status should prompt reassessment. The modu...

This module explores how risk status, clinical trajectory, right ventricular function, hemodynamics, and patient-specific factors inform the selection and escalation of PAH therapy. It reviews therapies targeting the endothelin, nitric oxide, prostacyclin, and activin signaling pathways and considers how combination therapy and route of administration can be individualized according to disease sev...

This module examines structured risk assessment as the foundation for goal-directed management of pulmonary arterial hypertension (PAH), emphasizing that clinical stability is not synonymous with low-risk status. It reviews validated risk-stratification approaches and the integration of functional capacity, biomarkers, imaging, and hemodynamics to assess prognosis and treatment response. The modul...

This module addresses the evolving management of patients who have achieved sustained clinical improvement but may experience treatment fatigue, adverse effects, or substantial treatment burden. It explores when therapy transition or de-escalation may be considered, emphasizing careful patient selection based on sustained clinical improvement, favorable risk status and hemodynamics, patient goals,...

This module focuses on translating PAH treatment strategy into an individualized, sustainable regimen by considering route of administration, titration, tolerability, and treatment burden. It examines the practical differences among oral, inhaled, subcutaneous, and intravenous therapies and how disease severity, treatment response, adverse effects, patient preferences, and capacity for self-manage...

This module establishes risk assessment as the foundation of treatment decision-making in pulmonary arterial hypertension (PAH). It reviews multidimensional risk stratification, treatment goals, and the use of clinical, functional, biomarker, imaging, and hemodynamic findings to guide initial therapy and subsequent reassessment. Through a high-risk PAH case, the module illustrates how treatment in...

asdf

Recent advances in idiopathic pulmonary fibrosis (IPF) continue to expand the evidence base, offering important insights into disease biology, therapeutic strategies, and ongoing research. However, clinicians often face challenges in interpreting and applying these insights within the context of evolving IPF care. In this What's New Doc video, Dr. Steven Nathan reviews the latest clinical trial fi...

Despite progress in disease identification and treatment strategies, PAH continues to carry considerable morbidity and mortality, highlighting the need for continued optimization of disease management. Throughout this educational podcast, Dr. Vallerie McLaughlin highlights the latest advances in PAH presented at the International 2026 Conference in Orlando, FL. Launch Date/Release Date : May 21 20...

In this expert-led podcast, Dr. Nathan shares practical insights on recognizing early indicators of PH in the setting of ILD, interpreting key diagnostic findings, and applying effective risk stratification strategies. The discussion focuses on improving early detection and optimizing management to ultimately enhance outcomes for this high-risk patient population. Launch Date/Release Date : May 7,...

New analyses show rising prevalence of progressive pulmonary fibrosis, persistent diagnostic delays, and continued gaps in antifibrotic use. Fresh data from major trials, including nerandomilast, inhaled treprostinil, admilparant, deupirfenidone, and nalbuphine ER for chronic cough, point to meaningful advances on the horizon. At the same time, patient-centered research highlights the need for cle...

Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life. Join Dr. Bose and...

Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life. Join Dr. Bose and...

Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life. Join Dr. Bose and...

Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life. Join Dr. Bose and...

In this 15-minute podcast, Dr. Steven Nathan reviews clinically significant presentations, posters, and abstracts presented in Chicago from October 19-22, 2025, that offer key insights for improving the diagnosis and management of interstitial lung disease (ILD). Launch Date/Release Date: October 23, 2025 Expiration Date: September 30, 2026 FACULTY Steven Nathan, MD Medical Director, Advanced Lung...

Clinicians usually face complex scenarios during screening for, diagnosing, and managing patients with ILD-PH. During this podcast epiosde, Dr. Jean Elwing discusses three case studies to illustrate the best-practice approaches to guide decisions and management: Case 1: A 68-year-old male with combined pulmonary fibrosis and emphysema Case 2: A 57-year-old male with IPF who presents with mild PH C...

During this educational podcast, Dr. Sonali Bose highlights the latest advances in COPD presented at the American Thoracic Society (ATS) International Conference in San Francisco, CA, May 17-21, 2025. Noteworthy presentations, posters, and abstracts are presented from the conference that are of high clinical significance to improve COPD. Launch Date: May 22, 2025 Release Date: May 22, 2025 Expirat...

Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this podcast episode, Dr....

Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven...